- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Zydus Lifesciences' subsidiary received US FDA Priority Review for saroglitazar NDA to treat PBC. This fast-tracks review, potentially accelerating its market entry.